【作者】 戴闽； 罗彩东；

【Author】 DAI Min;Luo Caidong;MianYang Central Hospital;

【机构】 四川绵阳中心医院；

【摘要】 目的研究国产阿加曲班在出血高风险患者急诊冠状动脉介入治疗中的安全性及疗效。方法出血高风险的147例急性心肌梗塞(AMI)患者,随机分为2组,在PCI术中分别用阿加曲班或比伐卢定抗凝治疗,测定激活的全血凝固时间(ACT)、手术成功率及30天无心血管事件生存率,主要安全性评价指标为轻度及重度出血。结果两组用药5min后的ACT均>225s,用药5min及手术结束时阿加曲班组A(T较比伐卢定组低(P<0.01)。术后停药阿加曲班组ACT恢复较比伐卢定组快(P<0.05)。PCI成功率及术后30天无心脏事件生存率无差异。阿加曲班组术后24h出血发生率较比伐卢定组低(5.46%vs 9.46%P<0.05),术后30天出血发生率较比伐卢定组低(8.22%vs12.16%P<0.05)。结论对于出血高风险的急性心肌梗死患者,国产阿加曲班是安全有效的抗凝制剂。更多还原

【Abstract】 Objective Research the anticogulant efficacy and safety of domestic argatroban for high risk of bleeding patients undergoing emergency percutaneous coronary intervention(PCI).Methods 147 acute myocardial infarction(AMI) patients that had high risk of bleeding were divided into the group of taking argatroban and taking bivalirudin.The activated coagulation time(ACT),the procedural success rate and the survival rate of two groups were compared.The major safety evaluation was based on mild or severe bleeding.Results Patients of two group had ACT > 225 s at 5 minutes after the medication during PCI.The ACT of argatroban group were lower than brgatroban group at 5min and after PCI.P <0.01,and the ACTs recovery were faster in argatroban group when after PCI.P <0.05.The procedural success rate and the survival rate of two group have no significant difference.The mild bleeding rate with in 24 hours in argatroban group and in brgatroban group were 5.46%and 9.46%.P <0.05.with in 30 days were 8.22%and12.16%,P <0.05.Conclusion Domestic argatroban could be used as an effective and safe anticogulant for high risk of bleeding patients undergoing emergency PCI.更多还原